NCT00367562已完成4 期
Phase IV Open Label Uncontrolled Trial of the Dual Blockade of the Renin Angiotensin System With Enalapril Plus Valsartan Combined With Oral Methylprednisolone for the Treatment of Proteinuria in IGA Nephropathy
Hospital Britanico1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 1996年1月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- DAILY PROTEINURIA
研究概览
简要总结
TO ASSESS THE EFFICACY OF THE RENIN ANGIOTENSIN SYSTEM PLUS STEROIDS TO DECREASE THE AMOUNT OF PROTEINURIA IN IGA NEPHROPATHY
详细描述
Patients whose proteinuria was > 0.5 g/day were to receive enalapril plus valsartan coupled with oral 0.5 g/day of methylprednisone for 6 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •PATIENTES WITH IGA NEPHROPATHY WITH PROTEINURIA OVER 0.5 G/DAY
排除标准
- •MALIGNANCY, RENAL FAILURE
结局指标
主要结局
DAILY PROTEINURIA
次要结局
- RENAL FUNCTION AS ASSESSED BY SERUM CREATININE
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Renin-angiotensin-aldosterone System (RAAS) Blockade and Contrast Induced NephropathyRadiographic Contrast Agent NephropathyNCT01525888Soroka University Medical Center100
招募中
4 期
Clinical Trial of renin-angiotensin-aldosterone system inhibitors with halting their administration and the effect on clinical outcomes of patients with coronavirus disease-2019 (COVID-19) referring to Sina and Imam-Khomeini Hospitals in 2020COVID-19.corona virus disease 2019U07.1IRCT20151113025025N3Tehran University of Medical Sciences60
已完成
2 期
Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney DiseaseDiabetic Kidney DiseaseNCT05593575Shanghai Pharmaceuticals Holding Co., Ltd305
已完成
不适用
Impact of continuing or withholding blood pressure reducing drugs on the blood pressure stability and quality of recovery following day surgery proceduresHaemodynamic instabilityAnaesthesiology - AnaestheticsACTRN12616001370493sha Gurunathan600
已完成
2 期
An Open Label, Safety Study to Assess the Potential for Adrenal SuppressionPlaque PsoriasisNCT02932878Taro Pharmaceuticals USA16